Clinical Trials Directory

Trials / Completed

CompletedNCT07028567

Subcision Followed by Diluted Calcium Hydroxylapatite Injection Versus Subcision Followed by Painting CROSS TCA Technique for the Treatment of Atrophic Acne Scars

Comparative Study of Subcision Followed by Diluted Calcium Hydroxylapatite Injection Versus Subcision Followed by Painting CROSS TCA Technique for the Treatment of Atrophic Acne Scars

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
13 (actual)
Sponsor
Tanta University · Academic / Other
Sex
All
Age
20 Years – 50 Years
Healthy volunteers
Not accepted

Summary

This study aimed to compare the safety and efficacy of subcision followed by diluted calcium hydroxyapatite injection versus subcision followed by the painting original chemical reconstruction of skin scars (CROSS) technique using trichloroacetic acid (TCA) for the treatment of atrophic acne scars.

Detailed description

Atrophic scars present as depressions secondary to fibrous contractions. Subcision is a technique in which a needle is inserted under the acne scar to sever the fibrous tissue (tethers) that bind down the scar. This releases the fibrous tissue. The original chemical reconstruction of skin scars (CROSS) technique using trichloroacetic acid (TCA) entails focal application of highly concentrated TCA (70% to 100%) with firm pressure applied to the entire atrophic area using a sharpened wooden applicator until frosting occurs. Fillers containing hyaluronic acid, calcium hydroxyapatite, and poly-L-lactic acid are increasingly used to correct atrophic acne scarring as they augment soft tissue in variable degree and are most effective in soft rolling or boxcar scars.

Conditions

Interventions

TypeNameDescription
DRUGCalcium hydroxylapatite fillerPatients received calcium hydroxylapatite filler (CaHA) (Radiesse®).
DRUGPainting chemical reconstruction of skin scars trichloroacetic acid techniquePatients received painting chemical reconstruction of skin scars (CROSS) trichloroacetic acid (TCA) technique.

Timeline

Start date
2023-01-01
Primary completion
2023-06-22
Completion
2023-06-22
First posted
2025-06-19
Last updated
2025-06-19

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT07028567. Inclusion in this directory is not an endorsement.